InvestorsHub Logo
Followers 8
Posts 394
Boards Moderated 0
Alias Born 07/22/2011

Re: None

Tuesday, 05/15/2018 6:44:26 AM

Tuesday, May 15, 2018 6:44:26 AM

Post# of 95
Good news for LVCLY. From latest PR:

"The one year follow up of the 18 patients in the Phase IIb study of NTCELL® for Parkinson’s disease shows a statistically significant improvement change in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III in the off state) in the patients who received 40 or 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery..The Data Safety Monitoring Board has advised that there are no safety issues arising from the data."